Vitex Pharmaceuticals

vitexpharma.com

Vitex Pharmaceuticals is a global leader in the contract manufacture of complementary medicine. From our state-of-the-art 26,000sqm best-in-class facility in Sydney, Australia, we are fully equipped to formulate, manufacture and package a wide variety of vitamins, minerals, herbal and nutritional supplements including tablets, softgel capsules, two-piece hardgel capsules and powders.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

LABCORP COMPLETES ACQUISITION OF PERSONAL GENOME DIAGNOSTICS

Labcorp | February 21, 2022

news image

Labcorp a leading global life sciences company, announced that it has closed its acquisition of Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products. The addition of PGDx and its technology complements and accelerates Labcorp’s existing liquid biopsy capabilities and expands Labcorp’s leading oncology portfolio of next-generation sequencing (NGS)-based genomic profiling capabilities, posit...

Read More

PHARMA TECH

AION LABS WELCOMES AMITI AS STRATEGIC PARTNER TO ACCELERATE ISRAEL'S POSITION AS A LEADING HUB FOR TRANSFORMATIVE AI-POWERED DRUG DISCOVERY INNOVATION

PR Newswire | January 09, 2024

news image

AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, announced today a new strategic partnership with Amiti Ventures, one of the leading early-stage venture capital firms in Israel. The partnership further strengthens the alliance of global leaders in pharma, biotech, and technology investment, expanding its offering as a venture studio and partner for new startups. "With a pr...

Read More

Pharmacy Market

EMA STARTS ROLLING REVIEW OF CUREVAC’S COVID-19 VACCINE (CVNCOV)

CureVac, EMA | February 18, 2021

news image

The European Medicines Agency (EMA's) Committee for Human Medicinal Products (CHMP) has begun a moving audit of CureVac AG's COVID-19 antibodies, CVnCoV. The survey was started on the grounds that starter research facility contemplates and early clinical preliminary outcomes recommend the immunization triggers the creation of antibodies and insusceptible cells that target SARS-CoV-2, the infection that causes COVID‑19. The survey will successively audit info...

Read More

Pharmacy Market

KEDALION THERAPEUTICS SECURES SERIES B FUNDING AND ANNOUNCES SIGNING OF OPTION TO ACQUIRE AGREEMENT

Kedalion Therapeutics, | November 16, 2021

news image

Kedalion Therapeutics is pleased to announce the completion of its Series B financing led by Novartis and involving a combination of new and existing investors. The Novartis investment includes an Exclusive Option to Acquire the company and its AcuStream™ technology. This agreement follows a Feasibility Study agreement with the AcuStream™ technology signed earlier this year. The subsequent feasibility study has been completed with successful results. Collaboration between the t...

Read More
news image

Business Insights

LABCORP COMPLETES ACQUISITION OF PERSONAL GENOME DIAGNOSTICS

Labcorp | February 21, 2022

Labcorp a leading global life sciences company, announced that it has closed its acquisition of Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products. The addition of PGDx and its technology complements and accelerates Labcorp’s existing liquid biopsy capabilities and expands Labcorp’s leading oncology portfolio of next-generation sequencing (NGS)-based genomic profiling capabilities, posit...

Read More
news image

PHARMA TECH

AION LABS WELCOMES AMITI AS STRATEGIC PARTNER TO ACCELERATE ISRAEL'S POSITION AS A LEADING HUB FOR TRANSFORMATIVE AI-POWERED DRUG DISCOVERY INNOVATION

PR Newswire | January 09, 2024

AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, announced today a new strategic partnership with Amiti Ventures, one of the leading early-stage venture capital firms in Israel. The partnership further strengthens the alliance of global leaders in pharma, biotech, and technology investment, expanding its offering as a venture studio and partner for new startups. "With a pr...

Read More
news image

Pharmacy Market

EMA STARTS ROLLING REVIEW OF CUREVAC’S COVID-19 VACCINE (CVNCOV)

CureVac, EMA | February 18, 2021

The European Medicines Agency (EMA's) Committee for Human Medicinal Products (CHMP) has begun a moving audit of CureVac AG's COVID-19 antibodies, CVnCoV. The survey was started on the grounds that starter research facility contemplates and early clinical preliminary outcomes recommend the immunization triggers the creation of antibodies and insusceptible cells that target SARS-CoV-2, the infection that causes COVID‑19. The survey will successively audit info...

Read More
news image

Pharmacy Market

KEDALION THERAPEUTICS SECURES SERIES B FUNDING AND ANNOUNCES SIGNING OF OPTION TO ACQUIRE AGREEMENT

Kedalion Therapeutics, | November 16, 2021

Kedalion Therapeutics is pleased to announce the completion of its Series B financing led by Novartis and involving a combination of new and existing investors. The Novartis investment includes an Exclusive Option to Acquire the company and its AcuStream™ technology. This agreement follows a Feasibility Study agreement with the AcuStream™ technology signed earlier this year. The subsequent feasibility study has been completed with successful results. Collaboration between the t...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us